	Breast Cancer Diagnosis and HER2+ Versus Triple Negative Discrimination by Infrared Spectral Histopathology. Anal Chem El Tahech H, Lerévérend C, Kane S, Fichel C, Hassani J, Trévoux S, Untereiner V, Lehmann-Che J, Maquin C, Corsois L, Merrouche Y, Vuiblet V, Bolko L, Salmon JH, Piot O, Potteaux S, Gobinet C. PMID: 42263021 [PubMed - as supplied by publisher]
	Less is more: The Role of preoperative ultrasound as a risk stratifying tool in identifying low volume axillary disease in breast cancer. Br J Radiol Salari Y, Rengabashyam B, Shafiei V. PMID: 42262900 [PubMed - as supplied by publisher]
	Barriers, Facilitators, and Intention to Use AI for Breast Cancer Diagnosis: Mixed Methods Study Among Austrian Physicians With and Without AI Experience. J Med Internet Res Kritz M, Holawatsch E, Behrens DA, Hyll W. PMID: 42262843 [PubMed - in process]
	Antibody-drug conjugates in breast cancer brain and leptomeningeal metastases: mechanistic insights and therapeutic progress. Cancer Metastasis Rev Zhang H, Qin Y, Chu H, Fan Y, Tang J, Deng W, Zheng X, Yuan Z, Zou Y, Kong Y. PMID: 42262659 [PubMed - in process]
	Experimental study of [(68)Ga]Ga-HER2-RGD, a dual-target molecular probe, for breast cancer PET/CT imaging. EJNMMI Res Zhao X, Dai M, Li T, Li N, Chen X, Dong B, Guo Y, Wei M, Zhao X, Zhang J. PMID: 42262467 [PubMed - as supplied by publisher]
	Differential effects of sevoflurane versus propofol on calmodulin expression in breast cancer patients. Pak J Pharm Sci Wang J, He B, Kuerban G, Gao C, Zhang B. PMID: 42262213 [PubMed - in process]
	Spiegelmer Aptamers: Innovative Approach in Breast Cancer. Breast Cancer (Auckl) Amiri Hezave Y, Najafi R, Amini R, Shojaeian A. PMID: 42261451 [PubMed]
	Association of Pegylated Liposomal Doxorubicin with Improved Overall Survival Compared with Epirubicin in Early-Stage Breast Cancer: A Population Based Study from Taiwan. Breast Cancer (Dove Med Press) Chen YC, Cheng MC, Chen PH, Chung CH, Chien WC, Dai MS, Chen JH, Huang TC. PMID: 42261320 [PubMed]
	Beyond Target Occupancy in Triple-Negative Breast Cancer: A Medicinal Chemistry Perspective on Modality-Guided Design for Durable Network Control. J Med Chem Zeng W, Chen Y, Neamati N, Jin Y. PMID: 42261123 [PubMed - as supplied by publisher]
	Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer. Exp Hematol Oncol Sahin TK, Orhan C, Ozercan IH, Muglu H, Er B, Akyildiz A, Tunbekici S, Oruc A, Aykan MB, Koylu B, Akdogan O, Onur ID, Ates O, Yazici O, Selcukbiricik F, Karadurmus N, Araz M, Erdem D, Goker E, Bilici A, Aksoy S, Guven DC. PMID: 42260640 [PubMed]
	Meta-analysis reveals pathological complete response benefits from neoadjuvant immuno-chemotherapy combination in patients with HER2-negative breast cancer. BMC Cancer Wei Y, Qi Y, Ge H, Zeng C, Li Q, Ma F. PMID: 42260448 [PubMed - as supplied by publisher]
	Constructing a prognostic survival model for patients with stage II-IV epithelial ovarian cancer: a study based on the SEER database and external validation in China. Sci Rep Ying L, Zhang Z, Sun X, Wang X, Zhou Y, Zhao L. PMID: 42260148 [PubMed - as supplied by publisher]
	A PML1-CCL5-PI3K/MAPK feedback loop governs survival of endocrine-resistant breast cancer cells. Cell Death Differ Wang H, Yun Z, Cao Y, Li X, Liu Z, Pai CP, Wu C, Yue J, Lin G, Cai J, Fang S, Li K, Willard B, Yang S, Keri RA, Schiemann WP, Diehl JA, Kao HY. PMID: 42260104 [PubMed - as supplied by publisher]
	First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial. Nat Cancer Schmid P, Im SA, Nowecki Z, Wysocki PJ, Jassem J, Jung KH, Lord S, Armstrong J, Stewart R, Vukovi, Denduluri N, Park YH. PMID: 42259988 [PubMed - as supplied by publisher]
	International consensus on axillary staging after neoadjuvant chemotherapy in node-positive breast cancer. Eur J Surg Oncol Lucocq J, Karakatsanis A, Kirwan C, Boughey J, Tseng J, Sun SX, Gentilini OD, Barber M, Chagla L, Buccimazza I, Dick L, Massannat Y, Dixon JM, Kühn T, Benson J, Elder K, NAC-AX Collaborative Group. PMID: 42259722 [PubMed - as supplied by publisher]
	Combined targeting of mesothelin and tenascin-C enhances CAR-T cell function and tumor microenvironment modulation in ovarian cancer. Mol Immunol Wang X, Zhang D, Wang T, Li X, Zhang J. PMID: 42259008 [PubMed - as supplied by publisher]
	Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004. Gynecol Oncol Tang X, Huang H, Peipert JD, Zola A, Buscema J, Yang K, Tew W, O'Cearbhaill RE, Muller C, Goodheart MJ, Moore RG, Liu R, Geller MA, Michener C, Chan J, Carney M, McNally L, Street D, Bookman MA, Moore KN, Liu JF, Wenzel L, Cella D. PMID: 42258989 [PubMed - as supplied by publisher]
	Scalp cooling outcomes in patients receiving trastuzumab deruxtecan for metastatic breast cancer. ESMO Open Salehi E, Chu X, Mayer EL, Singer S, Augdahl G, Stalteri M, Li T, Dibble KE, Sinclair N, Faggen M, Walsh J, Sammons S, Sendrick K, Hanna S, Mostaghimi A, Tayob N, LeBoeuf NR, Tolaney SM. PMID: 42258966 [PubMed - as supplied by publisher]
	Comparison of long-term survival between primary and interval cytoreductive surgery in advanced ovarian cancer: A ten-year real-world cohort study. Eur J Surg Oncol Duan X, Tan S, Wang C, Liu J, Huang L, Zhang Y. PMID: 42258952 [PubMed - as supplied by publisher]
	Headwinds in Breast Cancer Research: The Case for Pragmatic Radiotherapy De-escalation Studies. J Clin Oncol Braunstein LZ, Mitchell MP, Khan AJ, Sikov WM, Mamounas EP, Julian TB, Wolmark N. PMID: 42258793 [PubMed - as supplied by publisher]

Articles 1 - 20 / 329775

Page 1 of 16489



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy